Trials
2 active
15 in total · 3 in the EU
What this is
- How it works
- Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.-citinib: Janus kinase inhibitors WHO name stem
- Tested for
- Lichen Planopilaris, Cutaneous Sarcoidosis
- Main trialPhase 2/3
- “This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris”In the company’s words, NCT07532603 on ClinicalTrials.gov
- Other names
- PF-06700841
Coming up2
- 31 Dec 2028Phase 2/3 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 31 Dec 2028 | A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris | |
| Phase 2/3Recruiting | 31 Dec 2028 | A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis | |
| Phase 3Completed | 17 Jul 2025 | A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis | |
| Phase 2Completed | 6 Apr 2020 | A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis | |
| Phase 2Completed | 7 May 2020 | Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis | |
| Phase 2Completed | 5 Feb 2021 | A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects | |
| Phase 2Completed | 20 Apr 2021 | Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis | |
| Phase 2Completed | 10 May 2021 | Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | |
| Phase 2Completed | 10 Jan 2022 | A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa | |
| Phase 2Completed | 5 Oct 2023 | A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | |
| Phase 2Completed | 19 Oct 2023 | Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease | |
| Phase 2Completed | 30 Jul 2024 | A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis | |
| Phase 2Completed | 28 Feb 2025 | A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis | |
| Phase 1Completed | 11 Jan 2021 | Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations | |
| Phase 1Completed | 4 May 2022 | Renal Impairment Study of PF-06700841 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026